278 related articles for article (PubMed ID: 21203958)
1. Protein targets for structure-based anti-Mycobacterium tuberculosis drug discovery.
Lou Z; Zhang X
Protein Cell; 2010 May; 1(5):435-42. PubMed ID: 21203958
[TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
3. The tuberculosis structural genomics consortium: a structural genomics approach to drug discovery.
Musa TL; Ioerger TR; Sacchettini JC
Adv Protein Chem Struct Biol; 2009; 77():41-76. PubMed ID: 20663481
[TBL] [Abstract][Full Text] [Related]
4.
Jagadeb M; Rath SN; Sonawane A
J Biomol Struct Dyn; 2019 Aug; 37(13):3388-3398. PubMed ID: 30132739
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of potential druggable targets among hypothetical proteins of extensively drug resistant Mycobacterium tuberculosis (XDR KZN 605) through subtractive genomics approach.
Uddin R; Siddiqui QN; Azam SS; Saima B; Wadood A
Eur J Pharm Sci; 2018 Mar; 114():13-23. PubMed ID: 29174549
[TBL] [Abstract][Full Text] [Related]
6. Increasing the structural coverage of tuberculosis drug targets.
Baugh L; Phan I; Begley DW; Clifton MC; Armour B; Dranow DM; Taylor BM; Muruthi MM; Abendroth J; Fairman JW; Fox D; Dieterich SH; Staker BL; Gardberg AS; Choi R; Hewitt SN; Napuli AJ; Myers J; Barrett LK; Zhang Y; Ferrell M; Mundt E; Thompkins K; Tran N; Lyons-Abbott S; Abramov A; Sekar A; Serbzhinskiy D; Lorimer D; Buchko GW; Stacy R; Stewart LJ; Edwards TE; Van Voorhis WC; Myler PJ
Tuberculosis (Edinb); 2015 Mar; 95(2):142-8. PubMed ID: 25613812
[TBL] [Abstract][Full Text] [Related]
7. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
8. targetTB: a target identification pipeline for Mycobacterium tuberculosis through an interactome, reactome and genome-scale structural analysis.
Raman K; Yeturu K; Chandra N
BMC Syst Biol; 2008 Dec; 2():109. PubMed ID: 19099550
[TBL] [Abstract][Full Text] [Related]
9. Assessing the progress of Mycobacterium tuberculosis H37Rv structural genomics.
Fang Z; van der Merwe RG; Warren RM; Schubert WD; Gey van Pittius NC
Tuberculosis (Edinb); 2015 Mar; 95(2):131-6. PubMed ID: 25578513
[TBL] [Abstract][Full Text] [Related]
10. Colworth prize lecture 2016: exploiting new biological targets from a whole-cell phenotypic screening campaign for TB drug discovery.
Moynihan PJ; Besra GS
Microbiology (Reading); 2017 Oct; 163(10):1385-1388. PubMed ID: 28893361
[TBL] [Abstract][Full Text] [Related]
11. High throughput crystallography of TB drug targets.
Murillo AC; Li HY; Alber T; Baker EN; Berger JM; Cherney LT; Cherney MM; Cho YS; Eisenberg D; Garen CR; Goulding CW; Hung LW; Ioerger TR; Jacobs WR; James MN; Kim C; Krieger I; Lott JS; Sankaranarayanan R; Segelke BW; Terwilliger TC; Wang F; Wang S; Sacchettini JC
Infect Disord Drug Targets; 2007 Jun; 7(2):127-39. PubMed ID: 17970224
[TBL] [Abstract][Full Text] [Related]
12. The TB Structural Genomics Consortium: a decade of progress.
Chim N; Habel JE; Johnston JM; Krieger I; Miallau L; Sankaranarayanan R; Morse RP; Bruning J; Swanson S; Kim H; Kim CY; Li H; Bulloch EM; Payne RJ; Manos-Turvey A; Hung LW; Baker EN; Lott JS; James MN; Terwilliger TC; Eisenberg DS; Sacchettini JC; Goulding CW
Tuberculosis (Edinb); 2011 Mar; 91(2):155-72. PubMed ID: 21247804
[TBL] [Abstract][Full Text] [Related]
13. Mycobacterial genomics and structural bioinformatics: opportunities and challenges in drug discovery.
Waman VP; Vedithi SC; Thomas SE; Bannerman BP; Munir A; Skwark MJ; Malhotra S; Blundell TL
Emerg Microbes Infect; 2019; 8(1):109-118. PubMed ID: 30866765
[TBL] [Abstract][Full Text] [Related]
14. Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening.
Manjunatha UH; Smith PW
Bioorg Med Chem; 2015 Aug; 23(16):5087-97. PubMed ID: 25577708
[TBL] [Abstract][Full Text] [Related]
15. Mycobacterium tuberculosis: a model system for structural genomics.
Smith CV; Sacchettini JC
Curr Opin Struct Biol; 2003 Dec; 13(6):658-64. PubMed ID: 14675542
[TBL] [Abstract][Full Text] [Related]
16. Proteins with complex architecture as potential targets for drug design: a case study of Mycobacterium tuberculosis.
Mészáros B; Tóth J; Vértessy BG; Dosztányi Z; Simon I
PLoS Comput Biol; 2011 Jul; 7(7):e1002118. PubMed ID: 21814507
[TBL] [Abstract][Full Text] [Related]
17. Structural genomics of Mycobacterium tuberculosis: a preliminary report of progress at UCLA.
Goulding CW; Perry LJ; Anderson D; Sawaya MR; Cascio D; Apostol MI; Chan S; Parseghian A; Wang SS; Wu Y; Cassano V; Gill HS; Eisenberg D
Biophys Chem; 2003 Sep; 105(2-3):361-70. PubMed ID: 14499904
[TBL] [Abstract][Full Text] [Related]
18. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
[TBL] [Abstract][Full Text] [Related]
19. Cyclipostins and cyclophostin analogs inhibit the antigen 85C from
Viljoen A; Richard M; Nguyen PC; Fourquet P; Camoin L; Paudal RR; Gnawali GR; Spilling CD; Cavalier JF; Canaan S; Blaise M; Kremer L
J Biol Chem; 2018 Feb; 293(8):2755-2769. PubMed ID: 29301937
[TBL] [Abstract][Full Text] [Related]
20. The potential impact of structural genomics on tuberculosis drug discovery.
Arcus VL; Lott JS; Johnston JM; Baker EN
Drug Discov Today; 2006 Jan; 11(1-2):28-34. PubMed ID: 16478688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
